Loading…
← CockpitCompetitor Analysis › ROVI.MC Laboratorios Farmaceuticos Rovi, S.A.Open in the cockpit ↗

Laboratorios Farmaceuticos Rovi, S.A.ROVI.MCCompetitor analysis, valuation and peers

Spain · EUR·Health Care›Pharmaceuticals: Major

Spanish pharma company making injectable drugs (heparins) and providing fill-finish manufacturing, including for Moderna's vaccines.

≈ A smaller Catalent/injectable-drug specialistMomentum leader 92
Mkt cap
$3.75B
US dollars, full cap
Free float
32%
of shares outstanding
$/day
$9.82M
20-day average traded
Fwd P/E
21.9×
forward earnings
ROIC−WACC
+9.1 pp
WACC 5.7%
Hurdle
-11 pp
Req g minus delivered
Next earnings
98 days
24 Feb 2027
Close · EUR€67.60
1D-1.3%
1W-4.4%
1M+15.2%
3M+13.0%
6M+12.3%
YTD+6.5%
1Y+16.6%
ATR %2.3%
52w lowhigh22.0% off high

What Laboratorios Farmaceuticos Rovi does

Spanish pharma company making injectable drugs (heparins) and providing fill-finish manufacturing, including for Moderna's vaccines.

Pays its way from heparin sales plus contract manufacturing for other companies' injectables, Moderna among them. Its long-acting risperidone technology is licensed to Teva, which sells it in the US as Uzedy, so Rovi receives royalties and milestones rather than product sales. The López-Belmonte family controls the company.

In one line: A smaller Catalent/injectable-drug specialist.

Products and services

  • Enoxaparin (heparin) injectables
  • Contract fill-finish manufacturing
  • Long-acting injectable pipeline (risperidone ISM)
  • Biosimilars

Customers

  • Hospitals/health systems
  • Moderna (CDMO contract)

Where it sits in the supply chain

  • Health Care
  • Pharmaceuticals
  • Injectables manufacturing + own drug…

What could go right

  • CDMO demand for injectable/mRNA manufacturing
  • Own-pipeline drug launches

What could go wrong

  • Customer concentration (Moderna volumes)
  • Heparin/generic pricing pressure

Moat: narrow (process know-how, regulatory licence, customer qualification). Sterile-injectable and fill-finish expertise plus regulatory approvals are hard to replicate quickly.

Headquarters: Madrid, Spain · Founded: 1946 · Employees: 2,232

Named competitors

Laboratorios Farmaceuticos Rovi at a glance

Size Laboratorios Farmaceuticos Rovi (ROVI.MC) is a Spain Health Care company (Pharmaceuticals: Major) with a market value of $3.75B, the 32nd largest of 93 Spain companies the cockpit tracks. Shares closed at €67.60 on 18 Nov 2026.

Performance Over six months the shares gained 12.3%, against +1.6% for the median peer and +5.3% for the Spain market (cap-weighted) — 7th highest of 19 in its peer set.

Growth Revenue grew 14.4% over the last twelve months (peer median +8.4%); the operating margin is 20.2% (peer median 15.7%).

Valuation It trades at 21.9× forward earnings against a peer median of 19.9× (6th most expensive of 13).

Price implies For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -11 pp: the price already allows for a slowdown.

Capital Return on invested capital runs 9.1 points above its cost of capital (5.7% WACC).

Next results Next results expected around 24 Feb 2027 (exchange calendar; dates can move).

Relative performance

9010011021 May 202621 Aug 202618 Nov 2026ROVI.MC 112Peer median 103
Six months, rebased to 100: Laboratorios Farmaceuticos Rovi against the median of its 20 peers (local-currency closes).

Laboratorios Farmaceuticos Rovi financials

Reported figures in EUR; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
Revenue€829M€743M€764M€830M€818M
Revenue growth—-3%-8%+1%—
Gross profit€524M€452M€450M€464M€497M
EBITDA€204M€204M€207M€244M€277M
Net income€206M€140M€137M€170M€200M
Free cash flow€119M€120M€77.5M€60.6M€187M
Capital expenditure€79.7M€67.8M€62.2M€55.2M€51.4M
Total debt€101M€137M€126M€65.4M€72.2M

Quarterly statements and history in the cockpit →

Laboratorios Farmaceuticos Rovi competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

0%+50%+100%-25%0%+25%+50%600329TARS000513XENE688336SLSOGN3320128940DFTXWOCKPHARMASFZNACUTAAS1877ARQTROVI.MC6-month return →1-month return →
Up and to the right = strong over both horizons. Laboratorios Farmaceuticos Rovi is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×20×40×60×600329000513688336OGN6005213320128940SFZNACUTAASARQT000100ROVI.MCRevenue growth (TTM) →Forward P/E →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Laboratorios Farmaceuticos Rovi is the large dot.

Capital: growth delivered against growth the price implies

0%+100%+200%+300%0%200%600329TARS000513688336OGN301569ARQTROVI.MCGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Laboratorios Farmaceuticos Rovi is the large dot.

Laboratorios Farmaceuticos Rovi competitors and peer comparison

Head to head with its named competitors (ROVI.MC vs SDZ.SW vs GXI.DE vs 002399.SZ)
CompanyMarket cap6M returnRevenue growthOp. marginForward P/EReq g
Laboratorios Farmaceuticos Rovi ROVI.MC$3.75B+12%+14%20%21.9×1.2%
Sandoz SDZ.SW$41.7B+26%+1%15%24.5×7.5%
Gerresheimer GXI.DE$1.26B+21%+9%-4%16.0×57.0%
Shenzhen Hepalink Pharmaceutical 002399.SZ$1.80B-12%-6%8%25.8×-0.7%
Lonza LONN.SW$53.9B+36%-11%25%36.1×15.6%
Siegfried SFZN.SW$3.51B-17%+4%16%16.8×n/a
Samsung Biologics 207940.KS$48.7B-6%-20%43%34.4×7.0%
Fresenius SE & Co. KGaA FRE.DE$32.7B+41%+7%10%14.7×7.0%

How Laboratorios Farmaceuticos Rovi compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Laboratorios Farmaceuticos Rovi against its 20 peers (data as of 18 Nov 2026)
MeasureROVI.MCPeer medianRank in peer set
1-month return+15.2%-0.2%5th highest of 21
6-month return+12.3%+1.6%7th highest of 19
Distance from 52-week high-22.0%-29.5%9th highest of 21
Revenue growth (TTM)+14.4%+8.4%7th highest of 18
Operating margin20.2%15.7%5th highest of 17
Forward P/E21.9×19.9×6th most expensive of 13
Growth the price implies (Req g, 7 yrs)1.2%5.5%6th least demanding of 13
Growth delivered (Del g)+12.1%+6.7%4th highest of 13
Hurdle (Req g minus delivered)-10.9 pp-7.7 pp7th least demanding of 13
ROIC minus cost of capital+9.1 pp+4.3 pp6th highest of 18
EV / EBITDA17.0×25.3×5th cheapest of 10
Net debt / EBITDA0.1×0.2×5th least indebted of 10

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginForward P/EReq gDelivered g
Laboratorios Farmaceuticos Rovi ROVI.MCSpain$3.75B+12%+14%20%21.9×1.2%+12.1%
Tianjin Pharmaceutical Da Ren Tang 600329.SSChina$3.75B-10%-13%20%28.5×16.2%-5.8%
Tarsus Pharmaceuticals TARSUnited States$3.74B+17%+86%-10%n/a34.7%+159.5%
Livzon Pharmaceutical 000513.SZChina$3.76B+4%-14%19%16.9×-9.6%+2.7%
Xenon Pharmaceuticals XENEUnited States$3.71B-31%-100%n/an/an/an/a
Sunshine Guojian Pharmaceutical (Shanghai) 688336.SSChina$3.81B-38%+227%74%39.9×0.9%+45.1%
SELLAS Life Sciences SLSUnited States$3.66B+100%n/an/an/an/an/a
Organon & OGNUnited States$3.66B+3%-3%20%4.0×-4.1%-1.0%
Zhejiang Huahai Pharmaceutical 600521.SSChina$3.61B0%+10%12%20.1×6.4%+5.9%
China Resources Pharmaceutical 3320.HKHong Kong$3.60B-7%+8%4%5.8×-4.9%+7.8%
Novast Laboratories 301569.SZChina$3.92Bn/a+3%27%n/a57.4%+3.1%
HanmiPharm 128940.KSSouth Korea$3.95B-2%+14%16%15.0×4.7%+7.5%
Definium Therapeutics DFTXUnited States$3.99B+40%n/an/an/an/an/a
Wockhardt WOCKPHARMA.NSIndia$3.52B+25%+26%13%n/a58.0%+4.2%
Parabilis Medicines PBLSUnited States$3.52Bn/an/an/an/an/an/a
Siegfried SFZN.SWSwitzerland$3.51B-17%+4%16%16.8×n/an/a
Acutaas Chemicals ACUTAAS.NSIndia$3.50B+38%+45%36%63.6×n/an/a
Shanghai Junshi Biosciences 1877.HKHong Kong$3.49B-38%+36%-14%n/an/an/a
Arcutis Biotherapeutics ARQTUnited States$3.49B+35%+60%7%41.0×49.2%+367.3%
Jiangsu Nhwa Pharmaceutical 002262.SZChina$3.48B+8%+3%19%19.6×-2.1%+12.0%
Yuhan 000100.KSSouth Korea$4.11B-10%+8%6%40.4×n/an/a

Questions

Who are Laboratorios Farmaceuticos Rovi's main competitors?
Named competitors: Catalent (private or unlisted), Recipharm (private) (private or unlisted), Sandoz (SDZ.SW), Gerresheimer (GXI.DE), Shenzhen Hepalink Pharmaceutical (002399.SZ), Lonza (LONN.SW). The cockpit's measured peer set (industry) also includes Tianjin Pharmaceutical Da Ren Tang (600329.SS), Tarsus Pharmaceuticals (TARS), Livzon Pharmaceutical (000513.SZ), Xenon Pharmaceuticals (XENE), Sunshine Guojian Pharmaceutical (Shanghai) (688336.SS), SELLAS Life Sciences (SLS).
Is Laboratorios Farmaceuticos Rovi expensive compared with its peers?
On forward p/e it trades at 21.9× against a peer median of 19.9×, 6th most expensive of 13 in its peer set. For today's price to make sense, revenue must grow about 1% a year for seven years (Req g). Recent delivered growth is +12%, so the hurdle is -11 pp: the price already allows for a slowdown.
How has Laboratorios Farmaceuticos Rovi stock performed?
Over six months to 18 Nov 2026 the shares returned +12.3% against +1.6% for the median peer; over one year +16.6%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.